Freshfields advises Asieris on license agreement with Theramex
Freshfields advised Asieris Pharmaceutical, a biopharmaceutical company focused on genitourinary tumours and women’s health, on a conditional exclusive license agreement with Theramex, a specialty pharmaceutical company dedicated to women’s health.
The agreement concerns CEVIRA (APL-1702), a photodynamic drug-device combination product being developed as a potential non-surgical treatment for high-grade cervical lesions associated with human papillomavirus (HPV).
Deal details
Under the terms of the agreement, Theramex will receive exclusive rights and take responsibility for commercialising CEVIRA in Europe, Australia, New Zealand and Turkey, subject to applicable regulatory approvals. Asieris retains rights to the product in the rest of the world and will continue to support the programme through its development and manufacturing capabilities. The transaction structure includes an upfront payment, regulatory and commercial milestone payments, and tiered royalties, with the aggregate value of the deal exceeding US$250 million.
Advisory team
The Freshfields team advising Asieris was led by partners Elisabeth Wulf and Philipp Dohnke, both based in Hamburg, together with Ya Ma in Hong Kong. The team also included principal associate Maximilian Zellerhoff in Hamburg, associate Yichen Xing in Shanghai, and senior associate Ben Cohen in London.
